Overnight basal insulin requirements to maintain euglycemia were determined in five insulin-dependent diabetic subjects using a closed-loop insulin infusion system. A significant increase in hourly insulin requirements occurred between 0600 h and 0900 h as compared with 0100 h-0600 h. Although the increased insulin requirement was coincident with only the physiologic diurnal increase in plasma cortisol, the oral administration of the 11-beta hydroxylase inhibitor, metyrapone, decreased only the total overnight (0100 h-0900 h) basal insulin requirement, but not the early morning (0600 h-0900 h) rise in insulin required to maintain euglycemia. It would appear that although cortisol is an important counterregulatory factor, its diurnal elevation cannot account for the increase in early morning basal insulin requirements to maintain euglycemia in insulin-dependent diabetics. DIABETES 29:662-664, August 1980.
O vernight basal insulin requirements in fasting insulin-dependent diabetic subjects increase significantly during the early morning hours (0600 h -0900 h). Clarke et al. have demonstrated a two-to threefold increase in the amount of insulin required to maintain euglycemia from 0600 h to 0900 h as compared with 2400 h-0600 h using a feedback controlled (closed-loop) insulin infusion system. 1 Plasma glucose concentrations rise between 0600 h and 0800 h during constant insulin infusion provided by preprogrammable (open-loop) insulin delivery systems. 2 Consistent with these observations, Schmidt et al. have described increases in early morning blood glucose concentrations in patients treated with subcutaneous insulin.
hormone concentrations has demonstrated that plasma cortisol, but not plasma growth hormone or glucagon concentrations, increase synchronously with changes in blood glucose concentrations. 1 It has been suggested that insulin-requiring diabetic subjects have an increased sensitivity to physiologic rises in plasma cortisol 4 and that the normal diurnal variation in plasma cortisol, but not the content of the morning meal, contribute significantly to the increased morning insulin requirements observed in diabetic subjects. 1 To further study the importance of plasma cortisol on basal overnight insulin requirements, the physiologic increase in plasma cortisol concentrations was blocked with the 11-beta hydroxylase inhibitor, metyrapone, while blood glucose concentrations were controlled with a feedback controlled (closed-loop) insulin delivery system.
MATERIALS AND METHODS
Five insulin-dependent diabetic subjects, aged 16-27 yr, who were within 10% of ideal body weight 5 and who were free of microangiopathic complications, were studied. Each required subcutaneous insulin for at least 2 yr after initial presentation in ketoacidosis. Each subject or parent gave informed consent before admission to the Clinical Research Center of the University of Virginia Medical Center.
During each study, the subjects' blood glucose concentrations were controlled with a feedback controlled (closedloop) insulin delivery system (Biostator GCIIS, Miles Laboratory, Elkhart, Indiana). The characteristics of this system and its use in insulin-dependent diabetic subjects have been reported previously. 8 -7 Long-acting insulin was withheld and only regular insulin administered for 36 h before the initiation of the study. Each subject's blood glucose concentration was normalized during a 6-h equilibration period (1900 h-0100 h) preceding each study period (0100 h -0900 h) and each subject's blood glucose concentration was subsequently maintained at approximately 100 mg/dl for the duration of the study. Blood glucose concentrations and the amount of insulin infused were compiled each minute by the Biostator. Each subject was asleep at the onset of the study (0100 h). Each subject was studied on two occasions; a control day and a day during which metyrapone di-tartratei 750 mg orally every 4 h, was administered. This was begun 12 h before the study interval (0100 h-0900 h). No other medications were given. Each subject remained fasting throughout the study period.
Blood samples were obtained through an indwelling venous catheter for the determination of plasma cortisol, 11-deoxycortisol (compound S), growth hormone, and glucagon concentrations. Plasma cortisol was measured by radioimmunoassay with an antibody exhibiting 6.8% crossreactivity with 11-deoxycortisol. 8 Plasma 11-deoxycortisol was measured by radioimmunoassay with an antibody exhibiting less than 1% crossreactivity with cortisol 9 (Nichols Institute, San Pedro, California). Serum growth hormone was measured by a modification of the double antibody precipitation method, in which all incubations were performed at room temperature.
10 Samples for glucagon determination were collected in chilled trasylol-EDTA and measured by radioimmunoassay using 30K antisera.
11 All blood samples were immediately chilled, separated at 4°C and stored at -20°C until assayed.
The paired, two-tailed Student's t test was used for statistical analysis. All results are reported as mean ± SEM.
RESULTS
Mean blood glucose concentrations were maintained at 93 ± 1.6 mg/dl (range 72-122 mg/dl) from 0100 h to 0900 h on the control day and at 98 ± 2.2 mg/dl (range 72-140 mg/dl) from 0100 h to 0900 h on the metyrapone study day (P = NS, Table 1 ). Mean hourly basal insulin requirements were significantly greater on the control day than on the metyrapone study day (14.9 ± 1.0 mU/kg/h versus 9.7 ± 1.7 mU/kg/h, P < 0.005). However, mean hourly basal insulin requirements were significantly higher from 0600 h to 0900 h than from 0100 h to 0600 h on both the control day (17.5 ± 1.7 mU/kg/h versus 13.3 ± 2.1 mU/kg/h, P < 0.02) and the metyrapone study day (14.7 ± 0.9 mU/kg/h versus 6.6 ± 0.8 mU/kg/h, P < 0.005) ( Table 1) . Despite the increase in insulin administered from 0600 h to 0900 h on the metyrapone study day, the control algorithm which maintained euglycemia from 0100 h to 0600 h did not prevent a rise in blood glucose concentrations (91.9 ± 2.3 mg/dl versus 107.7 ± 2.9 mg/dl, P < 0.02). No significant rise in mean blood glucose concentration was observed during the control day.
During the control study, plasma glucagon averaged 88 ± 18 pg/ml at 2400 h and remained relatively constant through 0900 h. Mean serum growth hormone concentrations fell from 24.4 ± 7.1 ng/ml at 2400 h to 7.3 ± 4.0 at 0600 h and 6.5 ± 4.0 at 0900 h (P < 0.05). Mean plasma cortisol concentrations increased significantly from 2.9 ± 0.3/ng/dlat2400hto15.0 ± 3.2/ig/dl at 0600 h (P < 0.001) and remained elevated through 0900 h ( Table 2) .
During the metyrapone study, plasma glucagon concentrations averaged 92 ± 32 pg/ml at 2400 h and remained constant through 0900 h (93 ± 35 pg/ml). Mean serum growth hormone concentrations were elevated at 2400 h (20.7 ± 7 ng/ml), fell to 5 ± 2.1 ng/ml at 0600 h, and to 2.7 ± 0.4 ng/ml at 0900 h. Mean plasma cortisol concentra- TABLE 1 Mean blood glucose concentrations (mg/dl ± SEM) and mean insulin infusion rates (mU/kg/h ± SEM) from 0100 h to 0600 h and from 0600 h to 0900 h in 5 insulin-dependent diabetic subjects, and overajl mean blood glucose concentration (mg/dl ± SEM) and insulin infusion rate (mU/kg/h ± SEM) from 0100 h to 0900 h on control (C) day and metyrapone (M) study day. TABLE 2 Mean plasma glucagon (pg/ml ± SEM), growth hormone (ng/ml ± SEM), and cortisol (/xg/dl ± SEM) concentrations obtained at 2400 h, 0600 h, and 0900 h, in 5 insulin-dependent diabetic subjects on the control (C) day and the metyrapone (M) study day. 
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tions averaged 2.9 ± 0.7 /xg/dl at 2400 h and did not increase significantly at 0600 h (3.3 ± 0.4 /xg/dl) or at 0900 h (4.6 ± 0.6 /xg/dl) ( Table 2 ). Mean plasma 11-deoxycortisol concentrations averaged 4.0 ± 0.8 /tg/dl at 2400 h, increased significantly to 7.5 ± 1.3 /xg/dl (P < 0.02) by 0600 h, and averaged 9.6 ± 0.6 /tg/dl (P < 0.001) at 0900 h. Mean plasma glucagon and serum growth hormone concentrations were not different on the two study days. Mean plasma cortisol concentrations, however, were significantly higher on the control day than on the metyrapone study day.
DISCUSSION
The present study confirms previous reports of increased early morning insulin requirements to maintain euglycemia in insulin-dependent diabetic subjects.
1 " 3 The increase in basal insulin requirements occurs at a time (0600 h-0900 h) when plasma glucagon and serum growth hormone concentrations are low and plasma cortisol concentrations are elevated above overnight (2400 h-0600 h) levels. We have demonstrated, however, that enzymatic blockade of the physiologic rise in plasma cortisol does not alter the increased insulin requirement between 0600 h and 0900 h (Table 1) . Since metyrapone administration did not result in elevations of plasma glucagon or serum growth hormone concentrations above levels observed during the control study, neither of these counterregulatory factors can be implicated as etiologic for these findings.
Although plasma catecholamine concentrations were not determined in the present study, it is doubtful that they were responsible for the early morning increase in insulin requirements. Shamoon et al. have described enhanced sensitivity to both cortisol and epinephrine in insulin-dependent diabetic subjects. 4 However, the levels of plasma epinephrine in their study were similar to those observed during moderate hypoglycemia and no subject in the present study exhibited any signs of catecholamine excess (e.g., tachycardia, diaphoresis) during either the control or metyrapone study. Furthermore, it has been demonstrated in normal subjects that catecholamine concentrations are low during sleep and increase only with arousal and resumption of activity. 12 It has also been demonstrated that epinephrine synthesis is partially dependent on cortisol release, 13 which was negligible during metyrapone administration.
It is unlikely that increases in either 11-deoxycortisol or ACTH were responsible for the persistent increase in insulin requirements observed during the metyrapone study period. Exogenous administration of 11-deoxycortisol has no effect on carbohydrate tolerance.
14 Elevations in plasma ACTH do not prevent fasting hypoglycemia in patients with primary adrenal insufficiency, and high concentrations of ACTH have been shown to enhance glucose uptake in vitro. 15 Since the early morning increase in the insulin required to maintain euglycemia occurs with or without the physiologic diurnal increase in plasma cortisol concentrations, and since less insulin is required to maintain euglycemia when plasma cortisol is low, it would appear that although cortisol may be an important factor in the early morning increase in insulin requirement in diabetic subjects, its diurnal variation is not the sole factor responsible for this phenomenon.
